2seventy bio Reports Third Quarter Financial Results and Recent Operational Progress

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/23/2026

1. DECK
2. RNG
3. WDC
4. BYD
5. SPOT
6. WCN
7. BMY
8. FIX
9. TSCO
10. BE

Go back to 2seventy bio Reports Third Quarter Financial Results and Recent Operational Progress

Goldman Sachs Reiterates Sell Rating on 2Seventy Bio Inc. (TSVT)

November 12, 2024 12:52 PM EST

Goldman Sachs analyst Salveen Richter reiterated a Sell rating and $2.00 price target on 2Seventy Bio Inc. (NASDAQ: TSVT).

The analyst comments "TSVT reported 3Q US Abecma sales of $77mn (as reported by partner BMY) vs. GSe/Visible Alpha consensus of $70mn/$70mn, with Abecma profit-share of $11mn (vs. GSe/consesnus of $7mn/$11mn); GAAP EPS of ($0.19) was in line with consensus of ($0.19) (vs. GSe of ($0.34); Exhibit 1). While 3Q Abecma... More